Lexicon Pharma (LXRX) Tops Q4 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.42 -4.05%
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.04), $0.24 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $110 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Barclays Downgrades Dr. Martens Plc (DOCS:LN) to Underweight
- Reliance Industries (RELIANCE:IN) PT Lowered to INR1,840 at Goldman Sachs
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
